Cost-Effectiveness Thresholds in Healthcare Decision-Making: A Scoping Review of Methods, Interpretations, and Implications Across Countries
Author(s)
Belleman T1, Xander N2, Huic M3, Tesar T4, Çelik J1, Salcher-Konrad M5, Aas E6, Morgan K7, Rutten-van Mölken M8, Uyl-De Groot CA9
1Erasmus University Rotterdam, Amsterdam, NH, Netherlands, 2Erasmus University Rotterdam, School of Health Policy & Management, Rotterdam, Netherlands, 3HTA/EBM Center, Zagreb, Croatia, 4Comenius University in Bratislava, Bratislava, Slovakia, 5WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Gesundheit Österreich (Austrian National Public Health Institute/GÖG), Wien, 9, Austria, 6University of Oslo, Oslo, Norway, 7Myeloma Patients Europe, Brussels, Brussels, Belgium, 8Erasmus University Rotterdam, Erasmus School of Health Policy and Management (ESHPM) and Institute for Medical Technology Assessment (IMTA), Rotterdam, Netherlands, 9Erasmus University Rotterdam, Rotterdam, ZH, Netherlands
Presentation Documents
OBJECTIVES: Cost-effectiveness thresholds (CETs) enable consistent reimbursement decision making, ensuring cost-effective healthcare innovations. This study aimed to map current practices in determining CETs, the variation in values, and the usage and interpretation of CETs in countries that use them in routine decision-making.
METHODS: A scoping review of scientific literature from 2015 to September 2023 was conducted to identify method for determining CETs and country-specific practices. Only English language publications were included, with searches conducted in MedLine, Embase, and Web of Science Core Collection.
RESULTS: Out of 3,494 publications, 47 were found to be eligible for inclusion. Three main approaches for estimating CETs were identified: demand-side, supply-side, and GDP per capita. The demand-side approach values health gains based on societal willingness to pay, while the supply-side approach maximizes health benefits within budget constraints by considering opportunity costs. Literature suggests combining these approaches by setting a base CET with the supply-side method, varying based on population preferences or to include additional factors beyond the QALY. 19 countries were identified considering either an official or an unofficial CET in routine decision-making. Among these countries, variability was shown in how the CET was determined (2 supply-side, 3 demand-side, 8 GDP, 6 other), utilized, and interpreted. Current CET values based on GDP per capita, mostly in lower income countries, are possibly overestimated, as comparison of the ratio of CET value and GDP per capita, shows that these countries are willing to pay more for one additional QALY than other, mostly higher income, countries.
CONCLUSIONS: This review highlights the lack of consensus on CET determination methods, variations in methodology and interpretation, and the potential overestimation of CET values contributing to inefficient healthcare resource allocation. Adapting existing approaches to consider national requirements, societal preferences, and economic factors may be needed for more accurate CET determination.
Conference/Value in Health Info
Value in Health, Volume 27, Issue 12, S2 (December 2024)
Code
HPR251
Topic
Economic Evaluation, Health Policy & Regulatory
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis, Reimbursement & Access Policy, Thresholds & Opportunity Cost
Disease
No Additional Disease & Conditions/Specialized Treatment Areas